New Fortress Energy
NFE
DexCom
DXCM
Workday
WDAY
4
Ermenegildo Zegna NV
ZGN
5
Teradata Corp
TDC
US Stock MarketDetailed Quotes
PDSB PDS Biotechnology
- 1.260
- +0.030+2.44%
Trading Apr 24 11:29 ET
57.20MMarket Cap-1.22P/E (TTM)
1.280High1.220Low67.53KVolume1.230Open1.230Pre Close85.14KTurnover0.15%Turnover RatioLossP/E (Static)45.40MShares4.42052wk High3.01P/B55.42MFloat Cap0.85152wk Low--Dividend TTM43.98MShs Float17.850Historical High--Div YieldTTM4.88%Amplitude0.615Historical Low1.260Avg Price1Lot Size
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
PDS Biotechnology Stock Forum
Groundbreaking Cancer Immunotherapy Data: NCI Reveals PDS01ADC Clinical Results
Net loss for the year ended December 31, 2024, was approximately $37.6 million, or $1.03 per basic and diluted share, compared to a net loss of $42.9 million, or $1.39 per basic and diluted share, for the year ended December 31, 2023. The reduced net loss was primarily the result of decreased operating expenses, partially offset by increased net interest expense.
Research and development expenses for the year ended December 3...
Just
PDS Biotech Announces FDA Clearance of Ind Application for Combination of Versamune® Muc1 and PDS01ADC to Treat Metastatic Colorectal Cancer
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Thursday, 13th March at 8:00 am
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute
Second Versamune® platform candidate targets MUC1-positive solid tumors
U.S. Patent #12,201,685 covering methods of using combinations of the Versamune® platform and various immun...
Can This Triple Therapy Revolutionize HPV Cancer Treatment? 3.5x Better Survival Data
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology
Wednesday, 26th February at 8:00 am
Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months
Continued survival in the cohort of HPV16-positive immune checkpoint inhibitor naïve patients - mOS not yet reached
M...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (pres...
Cancer Breakthrough? PDS Biotech's HPV Treatment Shows Perfect Survival Rate in Latest Trial
Revolutionary HPV Cancer Therapy Enters Final Testing Phase: PDS Biotech's Landmark Trial Targets Growing Health Crisis
No comment yet